Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis

Zhu,Changxin; Song,Kerui; Shen,Zhaohua; Quan,Yongsheng; Tan,Bei; Luo,Weiwei; Wu,Shuai; Tang,Kai; Yang,Zhenyu; Wang,Xiaoyan

doi:10.3892/mmr.2018.8833

Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis

Authors:
- Changxin Zhu
- Kerui Song
- Zhaohua Shen
- Yongsheng Quan
- Bei Tan
- Weiwei Luo
- Shuai Wu
- Kai Tang
- Zhenyu Yang
- Xiaoyan Wang
View Affiliations

Affiliations: Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, School of Materials Science and Engineering, Central South University, Changsha, Hunan 410006, P.R. China
Published online on: March 29, 2018 https://doi.org/10.3892/mmr.2018.8833
Pages: 7567-7574
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Roseburia intestinalis (R. intestinalis) is one of the dominant intestinal bacterial microbiota and is decreased in patients with inflammatory bowel disease (IBD). It helps protect colonic mucosa against the development of inflammation and subsequent IBD, however its underlying mechanisms are unclear. The aim of the present study was to evaluate the anti‑inflammatory properties of R. intestinalis in vitro and in an animal model of IBD. The effects of R. intestinalis on disease activity index (DAI) scores, intestinal pathology, the expression of interleukin (IL)‑17 and the frequency of CD4+CD25+Foxp3+ regulatory T cells (Treg) were evaluated in vivo in a model of 2,4,6‑trinitrobenzenesulfonic acid solution (TNBS)‑induced colitis. Compared with the control group, TNBS‑treated mice had significantly higher secretion of IL‑17, higher DAI scores, a lower ratio of Treg, reduced colon lengths and higher histological scores for colon inflammation. The administration of R. intestinalis significantly downregulated the expression of IL‑17, increased the ratio of Treg and ameliorated the high DAI scores and the pathological signs of inflammation in the colon compared with mice treated with TNBS alone. Gene expression profiling was also used to detect the expression of IL‑17 in human IBD and healthy control specimens. To extend these findings to an in vitro model of inflammation the human colon epithelial cell line NCM460 was stimulated with lipopolysaccharide (LPS) to induce inflammation and co‑cultured with R. intestinalis and changes in IL‑17 expression were evaluated. R. intestinalis inhibited the LPS‑induced secretion of IL‑17 by NCM460 cells. In conclusion, these results demonstrate that R. intestinalis inhibits IL‑17 secretion and promotes Treg differentiation in colitis, suggesting that R. intestinalis could be of potential use in the treatment of IBD.

View Figures

View References

1	Baumgart DC and Sandborn WJ: Crohn's disease. Lancet. 380:1590–1605. 2012. View Article : Google Scholar : PubMed/NCBI
2	Danese S and Fiocchi C: Ulcerative colitis. N Engl J Med. 365:1713–1725. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ananthakrishnan AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–217. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 390:2769–2778. 2018. View Article : Google Scholar : PubMed/NCBI
5	Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M and Bernklev T: IBSEN Group: Work disability in inflammatory bowel disease patients 10 years after disease onset: Results from the IBSEN Study. Gut. 62:368–375. 2013. View Article : Google Scholar : PubMed/NCBI
6	Gionchetti P, Dignass A, Danese S, Dias Magro FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, et al: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis. 11:135–149. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kaplan GG and Ng SC: Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 152:313–321.e2. 2017. View Article : Google Scholar : PubMed/NCBI
8	Belkaid Y and Hand TW: Role of the microbiota in immunity and inflammation. Cell. 157:121–141. 2014. View Article : Google Scholar : PubMed/NCBI
9	Blander JM, Longman RS, Iliev ID, Sonnenberg GF and Artis D: Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 18:851–860. 2017. View Article : Google Scholar : PubMed/NCBI
10	Caballero S and Pamer EG: Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol. 33:227–256. 2015. View Article : Google Scholar : PubMed/NCBI
11	Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, Degnan PH, Booth CJ, Yu H and Goodman A: Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science. 347:170–175. 2015. View Article : Google Scholar : PubMed/NCBI
12	Miyoshi J and Chang EB: The gut microbiota and inflammatory bowel diseases. Transl Res. 179:38–48. 2017. View Article : Google Scholar : PubMed/NCBI
13	Eppinga H, Fuhler GM, Peppelenbosch MP and Hecht GA: Gut microbiota developments with emphasis on inflammatory bowel disease: Report from the Gut Microbiota for Health World Summit 2016. Gastroenterology. 151:e1–e4. 2016. View Article : Google Scholar : PubMed/NCBI
14	Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, et al: A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 63:1275–1283. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tilg H and Danese S: Roseburia hominis: A novel guilty player in ulcerative colitis pathogenesis? Gut. 63:1204–1205. 2014. View Article : Google Scholar : PubMed/NCBI
16	Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol. 14:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
17	van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS and Rudensky AY: Memory of inflammation in regulatory T cells. Cell. 166:977–990. 2016. View Article : Google Scholar : PubMed/NCBI
18	Himmel ME, Yao Y, Orban PC, Steiner TS and Levings MK: Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology. 136:115–122. 2012. View Article : Google Scholar : PubMed/NCBI
19	Krieglstein CF, Cerwinka WH, Laroux FS, Grisham MB, Schürmann G, Brüwer M and Granger DN: Role of appendix and spleen in experimental colitis. J Surg Res. 101:166–175. 2001. View Article : Google Scholar : PubMed/NCBI
20	Neurath MF, Fuss I, Kelsall BL, Stüber E and Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 182:1281–1290. 1995. View Article : Google Scholar : PubMed/NCBI
21	Cua DJ and Tato CM: Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol. 10:479–489. 2010. View Article : Google Scholar : PubMed/NCBI
22	Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P, Baldassano RN, Hyams JS, et al: Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis from colon-only Crohn's disease in treatment-naive pediatric patients. Gastroenterology. 152:1345–1357.e7. 2017. View Article : Google Scholar : PubMed/NCBI
23	Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP and Powrie F: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 208:1127–1133. 2011. View Article : Google Scholar : PubMed/NCBI
24	Vanhove W, Peeters PM, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De Schepper S, Van Lommel L, Reynaert NL, Schuit F, et al: Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm Bowel Dis. 21:2673–2682. 2015. View Article : Google Scholar : PubMed/NCBI
25	Olsen J, Gerds TA, Seidelin JB, Csillag C, Bjerrum JT, Troelsen JT and Nielsen OH: Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis. 15:1032–1038. 2009. View Article : Google Scholar : PubMed/NCBI
26	Sartor RB and Wu GD: Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 152:327–339.e4. 2017. View Article : Google Scholar : PubMed/NCBI
27	Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G and Rescigno M: Probiotic and postbiotic activity in health and disease: Comparison on a novel polarised ex-vivo organ culture model. Gut. 61:1007–1015. 2012. View Article : Google Scholar : PubMed/NCBI
28	Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, Chen H and Yu C: Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One. 9:e1091462014. View Article : Google Scholar : PubMed/NCBI
29	Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, et al: Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 500:232–236. 2013. View Article : Google Scholar : PubMed/NCBI
30	Duncan SH, Hold GL, Barcenilla A, Stewart CS and Flint HJ: Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 52:1615–1620. 2002. View Article : Google Scholar : PubMed/NCBI
31	Calderón-Gómez E, Bassolas-Molina H, Mora-Buch R, Dotti I, Planell N, Esteller M, Gallego M, Martí M, Garcia-Martín C, Martínez-Torró C, et al: Commensal-specific CD4(+) cells from patients with Crohn's disease have a T-Helper 17 inflammatory profile. Gastroenterology. 151:489–500.e3. 2016. View Article : Google Scholar : PubMed/NCBI
32	Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui T, Wei S, Liu Y, Wang Y, Vatan L, et al: Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. Oncoimmunology. 5:e11054302016. View Article : Google Scholar : PubMed/NCBI
33	Laidlaw BJ, Cui W, Amezquita RA, Gray SM, Guan T, Lu Y, Kobayashi Y, Flavell RA, Kleinstein SH, Craft J and Kaech SM: Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells. Nat Immunol. 16:871–879. 2015. View Article : Google Scholar : PubMed/NCBI
34	Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T, Rossmann P, Mrazek J, Kopecny J, Verdu EF and Tlaskalova-Hogenova H: Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 163:250–259. 2011. View Article : Google Scholar : PubMed/NCBI
35	Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ and Rudensky AY: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 504:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
36	Ding Y, Xu J and Bromberg JS: Regulatory T cell migration during an immune response. Trends Immunol. 33:174–180. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, Panagiotou G and El-Nezami H: Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc NatlAcad Sci USA. 113:E1306–E1315. 2016. View Article : Google Scholar